High basal NF-κB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives

British Journal of Cancer

Volumn 105, Issue 12, 2011, Pages 1874-1884

  Janjetovic, Z ^a   Brozyna, A A ^b   Tuckey, R C ^c   Kim, T K ^a   Nguyen, M N ^c   Jozwicki, W ^b   Pfeffer, S R ^a   Pfeffer, L M ^a   Slominski, A T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Melanin pigmentation; Melanoma; NF B; Vitamin D 3

Indexed keywords

20 HYDROXYVITAMIN D3; CALCITRIOL; COLECALCIFEROL DERIVATIVE; FORMALDEHYDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELANIN; PARAFFIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; COLECALCIFEROL;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; DNA BINDING; DNA SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; MELANOMA CELL; PIGMENTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTON TRANSPORT; TUMOR RESISTANCE; WESTERN BLOTTING; CELL DIVISION; DRUG EFFECT; MELANOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CELL DIVISION; CELL LINE, TUMOR; CHOLECALCIFEROL; HUMANS; MELANOMA; NF-KAPPA B;

EID: 84855985761     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.458     Document Type: Article

References (40)

1. Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, Eberle C, Barnhill R (2005) Sun exposure and mortality from melanoma. J Natl Cancer Inst 97(3): 195-199 (Pubitemid 40277369)
2. Bikle DD (2010) Vitamin D: newly discovered actions require reconsideration of physiologic requirements. Trends Endocrinol Metab 21(6): 375-384
3. Brozyna AA, Jozwicki W, Janjetovic Z, Slominski AT (2011) Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol 42(5): 618-631
4. Brozyna AA, VanMiddlesworth L, Slominski AT (2008) Inhibition of melanogenesis as a radiation sensitizer for melanoma therapy. Int J Cancer 123(6): 1448-1456
5. Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7(9): 684-700 (Pubitemid 47327412)
6. Dhawan P, Richmond A (2002) A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem 277(10): 7920-7928 (Pubitemid 34968242)
7. Dolcet X, Llobet D, Pallares J, Matias-Guiu X (2005) NF-kB in development and progression of human cancer. Virchows Arch 446(5): 475-482 (Pubitemid 40884279)
8. Du Z, Fan M, Kim JG, Eckerle D, Lothstein L, Wei L, Pfeffer LM (2009) Interferon-resistant Daudi cell line with a Stat2 defect is resistant to apoptosis induced by chemotherapeutic agents. J Biol Chem 284(41): 27808-27815
9. Egan KM (2009) Vitamin D and melanoma. Ann Epidemiol 19(7): 455-461
10. Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY, Thomas WD, Nguyen T, Hersey P (2001) The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 166(9): 5337-5345 (Pubitemid 32374152)
11. Harant H, Andrew PJ, Reddy GS, Foglar E, Lindley IJ (1997) 1alpha, 25-dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-kappaB-mediated interleukin-8 gene expression. Eur J Biochem 250(1): 63-71 (Pubitemid 27504583)
12. Holick MF (2003) Evolution and function of vitamin D. Recent Results Cancer Res 164: 3-28
13. Huang S, DeGuzman A, Bucana CD, Fidler IJ (2000) Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 6(6): 2573-2581 (Pubitemid 30399230)
14. Janjetovic Z, Tuckey RC, Nguyen MN, Thorpe Jr EM, Slominski AT (2010) 20,23-dihydroxyvitamin D3, novel P450scc product, stimulates differentiation and inhibits proliferation and NF-kappaB activity in human keratinocytes. J Cell Physiol 223(1): 36-48
15. Janjetovic Z, Zmijewski MA, Tuckey RC, DeLeon DA, Nguyen MN, Pfeffer LM, Slominski AT (2009) 20-Hydroxycholecalciferol, product of vitamin D3 hydroxylation by P450scc, decreases NF-kappaB activity by increasing IkappaB alpha levels in human keratinocytes. PLoS One 4(6): e5988
16. Karin M (2006) NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 45(6): 355-361
17. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2(4): 301-310 (Pubitemid 37328783)
18. Khanal RC, Nemere I (2007) The ERp57/GRp58/1,25D3-MARRS receptor: multiple functional roles in diverse cell systems. Curr Med Chem 14(10): 1087-1093 (Pubitemid 46672627)
19. Kinnaert E, Morandini R, Simon S, Hill HZ, Ghanem G, Van Houtte P (2000) The degree of pigmentation modulates the radiosensitivity of human melanoma cells. Radiat Res 154(5): 497-502
20. Li W, Tan D, Zenali MJ, Brown RE (2010) Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma. Int J Clin Exp Pathol 3(3): 238-243
21. Lin JY, Fisher DE (2007) Melanocyte biology and skin pigmentation. Nature 445(7130): 843-850
22. Lopez-Bergami P, Fitchman B, Ronai Z (2008) Understanding signaling cascades in melanoma. Photochem Photobiol 84(2): 289-306 (Pubitemid 351424029)
23. McNulty SE, Tohidian NB, Meyskens Jr FL (2001) RelA, p50 and inhibitor of kappa B alpha are elevated in human metastatic melanoma cells and respond aberrantly to ultraviolet light B. Pigment Cell Res 14(6): 456-465 (Pubitemid 34010073)
24. Meyskens Jr FL, Buckmeier JA, McNulty SE, Tohidian NB (1999) Activation of nuclear factor-kappa B in human metastatic melanoma cells and the effect of oxidative stress. Clin Cancer Res 5(5): 1197-1202 (Pubitemid 29233238)
25. Meyskens Jr FL, Farmer PJ, Yang S, Anton-Culver H (2007) New perspectives on melanoma pathogenesis and chemoprevention. Recent Results Cancer Res 174: 191-195
26. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, Chan M, Leake S, Karpavicius B, Haynes S, Kukalizch K, Whitaker L, Jackson S, Gerry E, Nolan C, Bertram C, Marsden J, Elder DE, Barrett JH, Bishop DT (2009) Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 27(32): 5439-5444
27. Pinczewski J, Slominski A (2010) The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms. Exp Dermatol 19(10): 860-864
28. Riis JL, Johansen C, Gesser B, Moller K, Larsen CG, Kragballe K, Iversen L (2004) 1alpha,25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured normal human keratinocytes through an increase in IkappaBalpha expression. Arch Dermatol Res 296(5): 195-202 (Pubitemid 39506515)
29. Slominski A, Ermak G, Wortsman J (1999) Modification of melanogenesis in cultured human melanoma cells. In Vitro Cell Dev Biol Anim 35(10): 564-565 (Pubitemid 30007652)
30. Slominski A, Paus R, Mihm MC (1998) Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis. Anticancer Res 18(5B): 3709-3715 (Pubitemid 28564252)
31. Slominski A, Semak I, Zjawiony J, Wortsman J, Li W, Szczesniewski A, Tuckey RC (2005) The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism. FEBS J 272(16): 4080-4090 (Pubitemid 41160916)
32. Slominski A, Tobin DJ, Shibahara S, Wortsman J (2004) Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84(4): 1155-1228 (Pubitemid 39287950)
33. Slominski A, Zbytek B, Slominski R (2009) Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. Int J Cancer 124(6): 1470-1477
34. Slominski AT, Janjetovic Z, Fuller BE, Zmijewski MA, Tuckey RC, Nguyen MN, Sweatman T, Li W, Zjawiony J, Miller D, Chen TC, Lozanski G, Holick MF (2010) Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show antileukemia effects, having low or absent calcemic activity. PLoS One 5(3): e9907
35. Slominski AT Kim TK, Janjetovic Z, Tuckey RC, Bieniek R, Yue J, Li W, Chen J, Nguyen MN, Tang EK, Miller D, Chen TC, Holick M (2011) 20-Hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells. Am J Physiol Cell Physiol 300(3): C526-C541
36. Soengas MS Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22(20): 3138-3151 (Pubitemid 36713766)
37. Van Waes C (2007) Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13(4): 1076-1082 (Pubitemid 46424045)
38. Wang D, Richmond A (2001) Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. J Biol Chem 276(5): 3650-3659
39. Yang J, Richmond A (2001) Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res 61(12): 4901-4909 (Pubitemid 32691908)
40. Zbytek B, Janjetovic Z, Tuckey RC, Zmijewski MA, Sweatman TW, Jones E, Nguyen MN, Slominski AT (2008) 20-hydroxyvitamin D3, a product of vitamin D3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation. J Invest Dermatol 128(9): 2271-2280